Lenvatinib for the treatment of renal cell carcinoma
Lenvatinib for the treatment of renal cell carcinoma
复制标题
DOI：
10.1080/13543784.2018.1472235
复制
发表时间：
2018-05
影响因子：
6.1
通讯作者：
G. Roviello;S. P. Corona;G. Bozza;M. Aieta;D. Generali;M. Rodriquenz;A. Mileo;M. Imperatori;A. Ianza;R. Conca;N. Sobhani
中科院分区：
文献类型：
--
作者：
G. Roviello;S. P. Corona;G. Bozza;M. Aieta;D. Generali;M. Rodriquenz;A. Mileo;M. Imperatori;A. Ianza;R. Conca;N. Sobhani
摘要引言：肾细胞癌（RCC）占所有实体瘤的2-3%。血管内皮生长因子（VEGF）受体的表达是RCC最常见的特征之一。Lenvatinib是一种新型多激酶抑制剂，已在几种实体瘤中进行了研究。乐伐替尼在肾细胞癌的治疗中已显示出良好的效果，尤其是与依维莫司联合治疗时。本文综述了乐伐替尼治疗晚期/转移性肾细胞癌的现有数据。专家意见：乐伐替尼联合依维莫司在临床和实验室研究中提供了令人鼓舞的结果，表明阻断血管生成和mTOR信号通路可能是治疗RCC的一种显着方法。作为这种方法的补充，在未来的临床环境中，乐伐替尼和依维莫司与免疫治疗的联合检测也是令人感兴趣的。
ABSTRACT Introduction: Renal cell carcinoma (RCC) accounts for 2–3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC. Areas covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma. Expert opinion: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy.